Once daily busulfan cyclophosphamide is well tolerated and effective as a preparative regimen for allogeneic hematopoietic stem cell transplant

Journal of Oncology Pharmacy Practice

Volumn 18, Issue 1, 2012, Pages 17-22

  Lemaistre, Julia A ^a   Bachier, Carlos ^a   Smith, Bradley ^a   Lemaistre, C F ^a   Shaughnessy, Paul J ^a  

^a TEXAS TRANSPLANT INSTITUTE   (United States)

Author keywords

allogeneic; Busulfan; cyclophosphamide

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; DRUG EFFICACY; DRUG FATALITY; DRUG TOLERABILITY; FEMALE; HUMAN; INTERMETHOD COMPARISON; KIDNEY FUNCTION; LIVER FUNCTION; LUNG DISEASE; MALE; MYELODYSPLASTIC SYNDROME; NEUROLOGIC DISEASE; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; SIDE EFFECT; VEIN OCCLUSION; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; BUSULFAN; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MIDDLE AGED; RETROSPECTIVE STUDIES; SURVIVAL RATE; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; WHOLE-BODY IRRADIATION; YOUNG ADULT;

EID: 84863404374     PISSN: 10781552     EISSN: 1477092X     Source Type: Journal    
DOI: 10.1177/1078155210392616     Document Type: Review

References (19)

1. Bensinger WI, Buckner CD Hematopoietic cell transplantation. Thomas ED Blume KG Forman SJ, ed. Malden, MA: Blackwell Science ; 1999: 123-134.
2. Santos GW, Tutschka PJ, Brookmeyer R, et al. Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. N Engl J Med. 1983 ; 309 (22). 1347-1353 (Pubitemid 14246556)
3. Lu C, Braine HG, Kaizer H, et al. Preliminary results of high dose busulfan and cyclophosphamide with syngeneic or autologous bone marrow rescue. Cancer Treat Rep. 1984 ; 68 (5). 711-717 (Pubitemid 14115195)
4. Tutschka PJ, Copelan EA, Klein JP. Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen. Blood. 1987 ; 70 (5). 1382-1388 (Pubitemid 18026142)
5. Socié G, Clift RA, Blaise D, et al. Busulfan plus cyclophosphamide compared with total- body irradiation plus cyclpphosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of 4 randomized studies. Blood. 2001 ; 98 (13). 3569-3574
6. Andersson BS, Madden T, Tran HT, et al. Acute safety and pharmacokinetics of intravenous busulfan when used with oral busulfan and cyclophosphamide as pretransplantation conditioning therapy: a phase I study. Biol Blood Marrow Transplant. 2000 ; 6 (5A). 548-554
7. Andersson BS, Kashyap A, Gian V, et al. Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: a phase II study. Biol Blood Marrow Transplant. 2002 ; 8 (3). 145-154 (Pubitemid 34285073)
8. Andersson BS, Thall PF, Madden T, et al. Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for IV BuCy2 in chronic myelogenous leukemia. Biol Blood Marrow Transplant. 2002 ; 8 (9). 477-485 (Pubitemid 35174821)
9. Madden T, de Lima M, Thapar N, et al. Pharmacokinetics of once-daily IV busulfan as part of pretransplantation preparative regimens: a comparison with an every 6-hour dosing schedule. Biol Blood Marrow Transplant. 2007 ; 13 (1). 56-64 (Pubitemid 46044090)
10. Andersson BS, de Lima M, Thall PF, et al. Once daily i.v. busulfan and fludarabine compares farorably with i.v. busulfan and cyclophosphamide as pretransplant conditioning therapy in AML/MDS. Biol Blood Marrow Transplant. 2008 ; 14 (6). 672-684 (Pubitemid 351664062)
11. Russell JA, Savoie ML, Balogh A, et al. Allogeneic transplantation for adult acute leukemia in first and second remission with a novel regimen incorporating daily intravenous busulfan, fludarabine, 400cGy total body irradiation, and thymoglobulin. Biol Blood Marrow Transplant. 2007 ; 13 (7). 814-821 (Pubitemid 46902436)
12. Russell JA, Tran HT, Quinlan D, et al. Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. Biol Blood Marrow Transplant. 2002 ; 8 (9). 468-476 (Pubitemid 35174820)
13. Bearman SI, Anderson GL, Mori M, et al. Venoocclusive disease of the liver: development of a model for predicting fatal outcomes after marrow transplantation. J Clin Oncol. 1993 ; 11 (9). 1729-1736 (Pubitemid 23277325)
14. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation. 1974 ; 18 (4). 295-304
15. Fernandez HF, Tran HT, Albrecht F, et al. Evaluation of safety and pharmacokinetics of administering intravenous busulfan in a twice-daily or daily schedule to patients with advanced hematologic malignant disease undergoing stem cell transplantation. Biol Blood Marrow Transplant. 2002 ; 8 (9). 486-492 (Pubitemid 35174822)
16. Williams CB, Day SD, Reed MD, et al. Dose modification protocol using intravenous busulfan and cyclophosphamide followed by autologous or allogeneic peripheral blood stem cell transplantation in patients with hematologic malignancies. Biol Blood Marrow Transplant. 2004 ; 10 (9). 614-623 (Pubitemid 39161875)
17. Hassan M, Ljungman P, Ringden O, et al. The effect of busulfan on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite: time interval influence on therapeutic efficacy and therapy-related toxicity. Bone Marrow Transplant. 2000 ; 25 (9). 915-924 (Pubitemid 30255722)
18. Ryu S, Lee J, Choi S, et al. Randomized comparison of four-times-daily versus once-daily intravenous busulfan in conditioning therapy for hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2007 ; 13 (9). 1095-1105 (Pubitemid 47215567)
19. Mamlouk K, Saracino G, Berryman RB, et al. Modification of the Bu/Cy myeloablative regimen using daily parenteral busulfan: reduced toxicity without the need for pharmacokinetic monitoring. Bone Marrow Transplant. 2005 ; 35 (8). 747-754 (Pubitemid 40613781)